Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9294MR)

This product GTTS-WQ9294MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9294MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15625MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ14136MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ6811MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ14152MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ4469MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ8953MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ12698MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ1789MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW